myocardial infarction
The patients with myocardial infarction after administration of alteplase had statistically significantly higher coronary flow (TIMI-3), 72.5% as compared to the patients who received streptokinase, 39.2%.
The patients with <span class="disease" id="19341228-6-18-39">myocardial infarction</span> after administration of <span class="gene" id="19341228-6-64-73">alteplase</span> had statistically significantly higher coronary flow (TIMI-3), 72.5% as compared to the patients who received streptokinase, 39.2%.